ESMO 2018 | ALTA-1L: brigatinib is superior to crizotinib in ALK+ NSCLC

Sanjay Popat

Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, provides an update on the results from the ALTA-1L (NCT02737501), a phase III study of brigatinib versus crizotinib in anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Brigatinib had superior results compared to crizotinib with regards to intracranial progression, the overall intracranial progression free survival hazard ratio was 0.27 following brigatinib treatment. Furthermore, when looking at both systemic and intracranial progression, brigatinib was again superior, even in those who had CNS metastasis at baseline. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video